02/02/23 9:00 AMNasdaq : VTGN acquisitionVistagen Announces Closing of Pherin Pharmaceuticals AcquisitionVistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and...RHEA-AIneutral
01/24/23 8:30 AMNasdaq : VTGN clinical trialVistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive DisorderVistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced the first cohort of healthy volunteers has been dosed in its U.S. Phase 1 clinical trial of PH10, the Company’ s investigational pherine nasal...RHEA-AIneutral
01/10/23 8:30 AMNasdaq : VTGN clinical trialVistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with AnxietyThe exploratory Phase 2 clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled study intended to evaluate efficacy, safety and tolerability of PH94B administered four times per day over four weeks for the treatment adjustment disorder with anxiety symptoms in adults. Michael Liebowitz, a former Columbia University...RHEA-AIneutral
12/30/22 8:30 AMNasdaq : VTGN Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment DisorderVistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders, today announced that the Company has taken important strategic steps to secure additional patent protection for its lead product candidate, PH94B, through...RHEA-AIneutral
12/21/22 8:30 AMNasdaq : VTGN acquisitionVistagen to Acquire Pherin PharmaceuticalsVistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders, and Pherin Pharmaceuticals, Inc., a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds...RHEA-AIpositive
12/06/22 8:30 AMNasdaq : VTGN Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive DisorderVistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced the U.S. Food and Drug Administration has granted Fast Track designation for the development of PH10, one of the Company’ s investigational...RHEA-AIvery positive
11/30/22 8:30 AMNasdaq : VTGN Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive DisorderVistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced receipt of a“ Study May Proceed” letter from the U.S. Food and Drug Administration. The letter greenlights a U.S. Phase 1 clinical trial under...RHEA-AIneutral
11/17/22 8:30 AMNasdaq : VTGN Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's DiseaseVistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced the publication of positive results from a preclinical study of the effects of AV-101, its oral NMDA receptor glycine site antagonist, in a...RHEA-AIneutral
11/10/22 4:30 PMNasdaq : VTGN earningsVistagen Reports Second Quarter Financial Results and Provides Corporate UpdateVistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today reported financial results for its fiscal year 2023 second quarter ended September 30, 2022 and provided a corporate update. Recent independent data...RHEA-AIneutral
11/04/22 8:30 AMNasdaq : VTGN conferencesearningsVistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced it will host a conference call and webcast on Thursday, November 10, 2022, at 2:00 p.m. Pacific Time to report financial results for its fiscal...RHEA-AIneutral